TrialNet is an international collaborative network that aims to prevent, delay and reverse the progression of type 1 diabetes, involving United States, Canada, Finland, United Kingdom, Italy, Germany, Australia and New Zealand.
TrialNet in Australia/New Zealand is led by A/Prof John Wentworth at Walter & Eliza Hall Institute (WEHI) in collaboration with Prof Peter Colman AM.
JDRF and the Type 1 Diabetes Clinical Research Network (T1DCRN) are proud to congratulate Professor John Shine AO and Professor Peter Colman for receiving Queen’s Birthday Honours this month. Read More
Two promising research projects have been targeted to receive contract seed funding grants, and will benefit from $350K in funding from the Type 1 Diabetes Clinical Research Network (T1DCRN), itself an innovative clinical research program led by JDRF Australia and funded by a Special Research Initiative through the Australian Research Council (ARC).
These two projects will explore new directions in curing and treating T1D and its complications. Read More
A new study has developed a prediction tool to help clinicians predict which newly diagnosed children and adolescents are unlikely to experience a period of remission.
The remission phase, also called the honeymoon phase, is the period of time after clinical diagnosis of T1D where the body can make just enough insulin (“endogenous” insulin) to control blood glucose levels either without needing insulin injections or with significantly lower doses. Read More
A new study has found that children with type 1 diabetes (T1D) who are hospitalised for Diabetic Ketoacidosis (DKA) are more likely to develop acute kidney injury (AKI), a sudden episode of renal failure or damage. DKA is a severe complication that occurs with prolonged hyperglycaemia. It may occur at the initial presentation of newly diagnosed T1D or in someone with pre-existing T1D in times of illness or insulin omission.
International diabetes registries report that many young people with type 1 diabetes (T1D) do not meet their recommended targets for glycaemic control, however relevant Australian data has been lacking. The Australasian Diabetes Data Network (ADDN) funded by the Type 1 Diabetes Clinical Research Network (T1DCRN) and led by the Australasian Paediatric Endocrine Society (APEG) and Australian Diabetes Society (ADS) is a secure, centralised database that captures de-identified clinical data from thousands of people after diagnosis of T1D on a single purpose built database. The ADDN study group has published the first national surveillance of glycaemic control and management of type 1 diabetes in young people in Australia.
There are a number of genes linked to type 1 diabetes (T1D), but not everyone with genetic predisposition develops the condition. This suggests that there are likely environmental triggers that stimulate the development of T1D. The Environmental Determinants of Diabetes in the Young (TEDDY), a study part supported by JDRF, is a large prospective, longitudinal cohort study investigating the environmental factors that may contribute to T1D development.
An article published by the TEDDY study group in Paediatric Diabetes this month highlights the benefits of early diagnosis of children at risk of T1D. Children involved in TEDDY are from six large clinical centres across the US and Europe and are being followed from birth until 15 years of age to track diet, illness, body growth and other life experiences.
Senator The Hon Simon Birmingham, Minister for Education and Training, and The Hon Greg Hunt MP, Minister for Health and Minister for Sport, have today announced the recipients of Innovation Award grants for research into type 1 diabetes.
Three bold, promising research projects have been selected and will benefit from $4.5 million in funding from the Type 1 Diabetes Clinical Research Network (T1DCRN), itself an innovative clinical research program led by JDRF Australia and funded by a Special Research Initiative through the Australian Research Council (ARC).
In an exciting paradigm shift that aims to accelerate patient impact, the research funded by the Innovation Award grants will explore new directions in the search for a cure for type 1 diabetes, including concepts that have never before been investigated.
A report by leading type 1 diabetes experts from around the world has for the first time provided consensus on managing blood glucose levels safely while exercising.
The report, ‘Exercise management in type 1 diabetes: a consensus statement’ was published in the Lancet Diabetes and Endocrinology journal and involved a team of 21 researchers, including T1DCRN researchers Professor Tim Jones, Professor Paul Fournier and Dr Carmel Smart. They undertook a review of current published studies to understand the activity levels of those living with type 1 diabetes and how different types of exercise affect blood glucose levels. Read More
JDRF is proud to congratulate Professor Mark Cooper, Head of Diabetes in the Faculty of Medicine, Nursing and Health Sciences at Monash University, who was awarded an AO (Officer in the General Division of the Order of Australia) on Australia Day this month.
This award is the most prestigious means of recognising outstanding members of the community at a national level.